OPKO Health (NASDAQ:OPK) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of OPKO Health (NASDAQ:OPK) in a report issued on Monday,Benzinga reports. HC Wainwright currently has a $3.00 price target on the biotechnology company’s stock.

Several other equities research analysts have also recently issued reports on the stock. Barrington Research reissued an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research report on Friday, February 28th. StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday, January 15th.

OPKO Health Price Performance

OPKO Health stock opened at $1.94 on Monday. The firm’s 50-day moving average is $1.56 and its two-hundred day moving average is $1.55. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health has a 12-month low of $0.86 and a 12-month high of $2.04. The stock has a market capitalization of $1.32 billion, a P/E ratio of -10.21 and a beta of 1.63.

OPKO Health (NASDAQ:OPK) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $183.60 million for the quarter, compared to analysts’ expectations of $155.42 million. Equities analysts predict that OPKO Health will post -0.25 earnings per share for the current year.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock in a transaction on Wednesday, December 11th. The shares were purchased at an average cost of $1.56 per share, with a total value of $780,000.00. Following the completion of the transaction, the chief executive officer now directly owns 212,411,477 shares in the company, valued at approximately $331,361,904.12. This represents a 0.24 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired a total of 1,389,971 shares of company stock valued at $2,124,442 over the last ninety days. Corporate insiders own 47.26% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC lifted its position in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 11,089 shares in the last quarter. Orion Portfolio Solutions LLC acquired a new position in shares of OPKO Health during the third quarter worth $45,000. Cibc World Markets Corp purchased a new position in shares of OPKO Health in the fourth quarter valued at $45,000. Zacks Investment Management acquired a new stake in OPKO Health during the 4th quarter valued at $49,000. Finally, Private Advisor Group LLC grew its holdings in OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 25,000 shares in the last quarter. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.